Adults who undergo a minimally invasive technique to treat atrial fibrillation are significantly less likely to die from a heart attack or heart failure, according to a long-term study by the University of Michigan Frankel Cardiovascular Center.
Rivaroxaban was more cost-effective than other anticoagulants for inpatient use in two retrospective studies that included patients undergoing joint replacement as well as those with atrial fibrillation or venous thromboembolism.
Innovative treatment approaches featured in the hot lines include vagal stimulation for systolic heart failure (NECTAR-HF), nitric oxide inhalation to reduce reperfusion injury in STEMI (NOMI) and the novel anti-Xa rivaroxaban for cardioversion (X-VERT).
Circumstantial evidence suggests that the innate immune system and coagulation system share a common evolutionary origin, which explains the extensive crosstalk between inflammatory cytokines and coagulation factors, with many components being important for both systems.
Just as heart attack symptoms may differ between men and women, so do stroke risks. Now, the American Heart Association has issued its first guidelines for preventing strokes in women. They focus on birth control, pregnancy, depression and other risk factors that women face uniquely or more frequently than men do.
Patients who have inherited antithrombin (AT) deficiencies face an increased risk for recurrent episodes of venous thromboembolism (VTE), according to a recent study by Italian researchers.
Worsening heart failure severity -- indicated by increasing doses of loop diuretics -- was associated in a dose-dependent manner with rising risks of developing diabetes, a Danish study showed.
Approximately 2.7 million Americans have atrial fibrillation - a form of arrhythmia that can lead to other heart complications, such as stroke. Now, new research finds that hospitalizations related to the condition are on the rise, as are costs to treat it.
Patients age 50 or younger have excellent and comparable immediate outcomes after undergoing either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) with similar long-term survival, according to a study published online May 5, 2014, ahead of print in the American Journal of Cardiology. However, for patients with ST-segment elevation myocardial infarction (STEMI), long-term survival was better with PCI.
Patients with cancer-associated venous thromboembolism and chronic kidney disease were at increased risk for major bleeding during anticoagulant treatment, according to study results.
Results from a large retrospective study suggest that controlling the activation of the renin-angiotensin system (RAS) with antihypertensive medications reduces the risk of atrial fibrillation.
New phase 2 data presented at the American Society of Hematology Annual Meeting demonstrate that andexanet alfa effectively reversed the anticoagulation activity of rivaroxaban.
Patients with atrial fibrillation are at higher risk for stroke in the first month after initiating treatment with the anti-clotting drug warfarin, study findings indicate.
Admission to hospital during pregnancy for reasons other than delivery carries a substantially increased risk of serious blood clots (known as venous thromboembolism or VTE), finds a study published in BMJ.
The use of novel oral anticoagulants in patients with atrial fibrillation is low in Europe, and compliance with European treatment guidelines for AF is suboptimal in those at the lowest and highest risk for stroke, according to a report by the European Society of Cardiology.
Fixed low-dose, ultrasound-assisted, catheter-directed thrombolysis rapidly reverses hemodynamic impairment in patients with higher-risk pulmonary embolism, according to a study published online December 13, 2013, ahead of print in the European Heart Journal.
Enhanced pacemaker technology sharply reduced progression of nonpermanent atrial fibrillation to permanent AF in patients with bradycardia and sinus node disease in the large international, randomized MINERVA trial.
Patients better adhered to their medication regimens in the year following hospitalization for acute coronary syndrome (ACS) when they were part of a program that included personalized attention from a pharmacist compared with usual care, according to a study by P. Michael Ho, M.D., Ph.D., of the Denver VA Medical Center, and colleagues.
Once-daily edoxaban is noninferior to warfarin for prevention of stroke or systemic embolism; and genotype-guided dosing of warfarin may be beneficial, according to three studies published online Nov. 19 in the New England Journal of Medicine.
Pregnant women who enter the hospital for reasons unrelated to their pregnancy face a sharply increased risk for thromboembolism during their stay and several weeks thereafter, a new study suggests.